Company Filing History:
Years Active: 2023-2024
Title: Marleen Keyaerts: Pioneering Innovations in Cancer Diagnosis and Treatment
Introduction
Marleen Keyaerts is a distinguished inventor based in Tervuren, Belgium, known for her significant contributions in the field of cancer research. With a portfolio of two patents, she has demonstrated her commitment to developing cutting-edge solutions aimed at improving cancer diagnosis and therapy.
Latest Patents
Keyaerts' latest innovations include two notable patents. The first patent revolves around the development of human PD-L1-binding immunoglobulins. This invention concerns polypeptides that incorporate an immunoglobulin domain capable of binding to human Programmed Death Ligand-1 (huPDL1). The applications of these polypeptides are diverse, including their utilization as medicaments or diagnostic agents, such as immunotraders.
The second patent pertains to radio-labelled antibody fragments designed for cancer prognosis and diagnosis, as well as predicting responses to cancer therapy. This application features polypeptides consisting of at least one heavy chain variable domain that specifically binds to target proteins found on solid tumors, like HER2. Additionally, it encompasses nucleic acids that encode such polypeptides, methods for their preparation, and pharmaceutical compositions that include these innovative components.
Career Highlights
Marleen Keyaerts is affiliated with the Vrije Universiteit Brussel, where she continues to push the boundaries of medical science through her research. Her academic background and extensive experience empower her to develop life-changing solutions that address critical healthcare challenges.
Collaborations
Throughout her career, Keyaerts has collaborated with esteemed colleagues like Nick Devoogdt and Tony Lahoutte. These partnerships have further enriched her projects and facilitated a synergistic approach to advancing cancer research.
Conclusion
Marleen Keyaerts is a trailblazer in the realm of cancer diagnosis and treatment innovations. Her patents reflect a significant leap in the understanding and management of cancer. As she continues her work at the Vrije Universiteit Brussel, her contributions are poised to make a lasting impact on the future of oncological therapies.